Avid Bioservices Welcomes Dave Stewart as New Chief Technology and Transformation Officer
Avid Bioservices, Inc., a leading Contract Development and Manufacturing Organization (CDMO) specializing in biologics, has announced the appointment of Dave Stewart to the newly created role of Chief Technology and Transformation Officer (CTTO). This strategic move is aimed at advancing the company’s growth and expansion plans as it continues to establish itself as a trusted partner in the biopharmaceutical industry.
Kenneth Bilenberg, the CEO of Avid Bioservices, expressed optimism about Stewart's leadership, noting that this new position signals a significant step in positioning Avid for its next phase of growth. In his statement, Bilenberg emphasized that the company is committed to becoming the most reliable and proactive external partner in all phases of development and manufacturing. "Avid has gained significant momentum in recent years, and as we look to the future, we are strategically investing in our personnel, processes, and systems that will drive our growth," Bilenberg remarked.
Stewart's role will involve overseeing the integration of technology and transformation initiatives throughout Avid’s development and manufacturing networks. His focus will be on digital modernization, automation, and the incorporation of advanced tools and service capabilities. Working closely with the Avid team, Stewart aims to enhance the company’s systems and platforms, ensuring that they align with the company’s expansion efforts while increasing efficiency and flexibility.
"I have long admired Avid’s reputation for quality and unwavering focus on patient outcomes," said Stewart. "The commitment to doing things right is evident in every aspect of the work being done here. Joining this team during such a dynamic phase of growth is a tremendous opportunity to contribute to a mission I believe in."
The introduction of the CTTO role underscores Avid's dedication to continuous improvement and maintaining strong partnerships with customers. It ensures the company remains agile and forward-thinking as it expands its capabilities and services across its facilities. Avid Bioservices is known for its expertise in developing mammalian cell culture products, operating out of the U.S. with a pristine record from the FDA. Biopharmaceutical innovators around the globe rely on Avid’s agility and ability to navigate complex regulatory landscapes, making it a trusted partner from development through to commercial delivery.
With over 600 batches manufactured and more than 275 commercial batches delivered worldwide, Avid’s track record speaks to its reliability and quality. The company has successfully passed inspections from regulatory authorities, promoting a standard of excellence within the industry. Stewart’s appointment aligns with the necessity for Avid to continue advancing its operational capabilities in response to the evolving biopharmaceutical market, making this a pivotal moment for both Avid Bioservices and its clients.
In summary, Avid Bioservices is poised for continued success as Dave Stewart steps into his new role, demonstrating the company’s commitment to innovation, quality, and partnership in the biopharmaceutical arena.
Kenneth Bilenberg, the CEO of Avid Bioservices, expressed optimism about Stewart's leadership, noting that this new position signals a significant step in positioning Avid for its next phase of growth. In his statement, Bilenberg emphasized that the company is committed to becoming the most reliable and proactive external partner in all phases of development and manufacturing. "Avid has gained significant momentum in recent years, and as we look to the future, we are strategically investing in our personnel, processes, and systems that will drive our growth," Bilenberg remarked.
Stewart's role will involve overseeing the integration of technology and transformation initiatives throughout Avid’s development and manufacturing networks. His focus will be on digital modernization, automation, and the incorporation of advanced tools and service capabilities. Working closely with the Avid team, Stewart aims to enhance the company’s systems and platforms, ensuring that they align with the company’s expansion efforts while increasing efficiency and flexibility.
"I have long admired Avid’s reputation for quality and unwavering focus on patient outcomes," said Stewart. "The commitment to doing things right is evident in every aspect of the work being done here. Joining this team during such a dynamic phase of growth is a tremendous opportunity to contribute to a mission I believe in."
The introduction of the CTTO role underscores Avid's dedication to continuous improvement and maintaining strong partnerships with customers. It ensures the company remains agile and forward-thinking as it expands its capabilities and services across its facilities. Avid Bioservices is known for its expertise in developing mammalian cell culture products, operating out of the U.S. with a pristine record from the FDA. Biopharmaceutical innovators around the globe rely on Avid’s agility and ability to navigate complex regulatory landscapes, making it a trusted partner from development through to commercial delivery.
With over 600 batches manufactured and more than 275 commercial batches delivered worldwide, Avid’s track record speaks to its reliability and quality. The company has successfully passed inspections from regulatory authorities, promoting a standard of excellence within the industry. Stewart’s appointment aligns with the necessity for Avid to continue advancing its operational capabilities in response to the evolving biopharmaceutical market, making this a pivotal moment for both Avid Bioservices and its clients.
In summary, Avid Bioservices is poised for continued success as Dave Stewart steps into his new role, demonstrating the company’s commitment to innovation, quality, and partnership in the biopharmaceutical arena.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.